MEK activation is associated with a molecular subgroup in high grade serous ovarian cancer

被引：0
|
作者：
McCabe, Nuala
Gourley, Charlie
McGavigan, Andrena
Michie, Caroline .
McGivern, Niamh
Churchman, Michael
O'Brien, Eamonn J.
Hill, Laura
Davison, Timothy S.
Williams, Alistair
McCluggage, Glenn
Keating, Karen E.
Harkin, Denis P.
Kennedy, Richard D.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
453
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Molecular Management of High-Grade Serous Ovarian Carcinoma
    Punzon-Jimenez, Paula
    Lago, Victor
    Domingo, Santiago
    Simon, Carlos
    Mas, Aymara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [32] Novel Hypoxia-Associated Markers of Chemoresistance in High Grade Serous Ovarian Cancer
    McEvoy, L.
    O'Toole, S. A.
    Spillane, C. D.
    Stordal, B.
    Gallagher, M.
    Martin, C. M.
    Norris, L.
    Gleeson, N.
    McGoldrick, A.
    Furlong, F.
    McCann, A.
    Sheils, O.
    O'Leary, J. J.
    JOURNAL OF PATHOLOGY, 2015, 237 : S13 - S13
  • [33] MEK INHIBITOR TRAMETINIB IN HIGH GRADE OVARIAN CANCER PROLIFERATION
    Chesnokov, Mikhail
    Jamroze, Anmbreen
    Ha, Wootae
    Chefetz, Ilana
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 82 - 82
  • [34] Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma
    Morse, Christopher B.
    Norquist, Barbara M.
    Harrell, Maria I.
    Agnew, Kathy J.
    Gray, Heidi J.
    Urban, Renata R.
    Garcia, Rochelle L.
    Goff, Barbara A.
    Swisher, Elizabeth M.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (02) : 389 - 392
  • [35] Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma
    Morse, C.
    Norquist, B.
    Bernards, S.
    Harrell, M.
    Agnew, K.
    Swisher, E.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 196 - 196
  • [36] Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancer
    Nguyen, Nancy
    Brooks, Rebecca
    Leiserowitz, Gary
    Chien, Jeremy
    GYNECOLOGIC ONCOLOGY, 2022, 164 (01) : E3 - E4
  • [37] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [38] Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
    Sundar, Raghav
    Tan, David
    Lei, Lim S.
    Chia, Whay-Kuang
    CURRENT CANCER THERAPY REVIEWS, 2016, 12 (01) : 23 - 36
  • [39] PREDICTORS OF MEK INHIBITOR RESPONSE IN LOW GRADE SEROUS OVARIAN CANCER CELL LINES.
    Carey, M.
    Dawson, A.
    Hoenisch, J.
    Kim, H.
    Chui, K.
    Bamford, S.
    Salamanca, C.
    Cremona, M.
    Anderson, S.
    Volik, S.
    Le Bihan, S.
    Collins, C.
    Morin, G.
    Huntsman, D.
    DiMattia, G.
    Hennessy, B.
    Llaurado-Fernandez, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 135 - 135
  • [40] MOLECULAR SUBTYPES OF OVARIAN CANCER: INSIGHTS INTO THE DRIVERS OF HIGH-GRADE OVARIAN SEROUS AND CLEAR CELL TUMOURS
    Bowtell, D. D. L.
    ANNALS OF ONCOLOGY, 2010, 21 : 30 - 30
12345